icon-folder.gif   Conference Reports for NATAP  
 
  DDW Liver Conference
 
San Francisco, May 19-22, 2002
Back grey_arrow_rt.gif
 
 
 
Prediction of Early Virologic Response to Pegasys plus Ribavirin in Patients with Genotype 1: can 24 hour viral load response predict 72 week outcome
 
Reported by Jules Levin
 
  Prediction of Early Virologic Response to Pegasys plus Ribavirin in Patients with Genotype 1: can 24 hour viral load response predict 72 week outcome
 
The hypothesis for this study is that the initial virologic response may be useful to characterize the likely subsequent response to therapy. For background, Peter Ferenci (Austria) reported that viral decline (of <0.8 log ) 24 hours after a single dose of standard IFN predicts nonresponse to IFN/RBV combination therapy 100% of the time (Jessner et al, Lancet 2001). And absence of a virologoic response (of >2 log) after 12 weeks of Pegasys/RBV (Fried et al, DDW 2001) results 97% of the time in no sustained response (Ferenci et al, AASLD 2001).
 
In the Jessner study patients who were treated with IFN 9 or 10 MU dose of standard interferon and then received IFN/RBV (26 pts IFN/RBV, 21 pts Pegasys/RBV). The patients who achieved with IFN monotherapy >1.4 log reduction in viral load in the first 24 hours achieved an SVR (sustained viral response) 100% of the time with combination Pegasys/RBV; patients with 1.4 to 0.8 log reduction had SVR 33% of the time and patients with <0.8 log reduction achieved SVR 7.2% of the time.
 
The goal of the currently reported study at DDW by Peter Ferenci in an oral presentation was to see if this approach is valid in an ongoing study to see if using the IFN-sensitivity test can predict the 12-week virologic response to Pegasys/RBV. In preliminary study the 12 week viral load response has been shown to have predictive ability for a sustained response (Ferenci, AASLD 2001).
 
The target number of patients for enrollment in this study is 220. 138 have been screened, 116 randomized and 65 have been treated for >12 weeks. 8 patients discontinued before week 12. So these reported results are preliminary as the study has not yet been completed. Patients received 180 mcg Pegasys+ 1000/1200 RBV with amantadine or amantadine placebo.
 
PRELIMINARY RESULTS
 
Patients who were HCV-negative at week 12 (n=42) had a 1.17 log decline from baseline 24 hours after a 9 MU IFN dose. Patients who were HCV-positive at week 12 had a 0.59 log decline from baseline 24 hrs after a 9 MU IFN dose. The difference was statistically significant (p=0.00006). There was no difference in baseline viral load between the group of patients who were HCV positive or negative.
 
14/15 patients with >1.4 log decline were viral responders at week 12 while 1 patient was not. 18/25 patients with 0.8-1.39 log decline were responders while 7 were not. Only 10/28 patients with <0.8 log decline were responders but this shows that some patients did respond with less than a 0.8 viral load decline.
 
After 24 weeks of therapy 10/10 patients who had a decline in viral load 24 hrs after a dose of 9 MU IFN were HCV-negative. 17/19 of patients with 0.8-1.39 log decline were HCV-negative. And 10/17 with <0.8 log decline were HCV-negative.
 
The authors concluded that the decline in viral load after one dose of standard IFN may predict the outcome of Pegasys/RBV therapy. Patients with less of a response in 24 hrs to a dose of IFN may also be effective. These findings should be studied further.